Cargando…

IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA

BACKGROUND: Diffuse midline gliomas (DMG) are lethal pediatric brain tumors with dismal prognoses. Presently, MRI is the mainstay of disease diagnosis and surveillance. We aimed to identify prognostic image-based radiomics markers of DMG and compare its performance to clinical variables at presentat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Lydia, Han, Michelle, Wright, Jason, Toescu, Sebastien, Campion, Andrew, Shpanskaya, Katie, Mankad, Kshitij, Ho, Chang, Lober, Robert, Cheshier, Samuel, Hargrave, Darren, Jacques, Tom, Aquilina, Kristian, Monje, Michelle, Grant, Gerald, Mattonen, Sarah, Vitanza, Nick, Yeom, Kristen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715677/
http://dx.doi.org/10.1093/neuonc/noaa222.346
_version_ 1783619011047587840
author Tam, Lydia
Han, Michelle
Wright, Jason
Toescu, Sebastien
Campion, Andrew
Shpanskaya, Katie
Mankad, Kshitij
Ho, Chang
Lober, Robert
Cheshier, Samuel
Hargrave, Darren
Jacques, Tom
Aquilina, Kristian
Monje, Michelle
Grant, Gerald
Mattonen, Sarah
Vitanza, Nick
Yeom, Kristen
author_facet Tam, Lydia
Han, Michelle
Wright, Jason
Toescu, Sebastien
Campion, Andrew
Shpanskaya, Katie
Mankad, Kshitij
Ho, Chang
Lober, Robert
Cheshier, Samuel
Hargrave, Darren
Jacques, Tom
Aquilina, Kristian
Monje, Michelle
Grant, Gerald
Mattonen, Sarah
Vitanza, Nick
Yeom, Kristen
author_sort Tam, Lydia
collection PubMed
description BACKGROUND: Diffuse midline gliomas (DMG) are lethal pediatric brain tumors with dismal prognoses. Presently, MRI is the mainstay of disease diagnosis and surveillance. We aimed to identify prognostic image-based radiomics markers of DMG and compare its performance to clinical variables at presentation. METHODS: 104 treatment-naïve DMG MRIs from five centers were used (median age=6.5yrs; 18 males, median OS=11mos). We isolated tumor volumes of T1-post-contrast (T1gad) and T2-weighted (T2) MRI for PyRadiomics high-dimensional feature extraction. 900 features were extracted on each image, including first order statistics, 2D/3D Shape, Gray Level Co-occurrence Matrix, Gray Level Run Length Matrix, Gray Level Size Zone Matrix, Neighboring Gray tone Difference Matrix, and Gray Level Dependence Matrix, as defined by Imaging Biomarker Standardization Initiative. Overall survival (OS) served as outcome. 10-fold cross-validation of LASSO Cox regression was used to predict OS. We analyzed model performance using clinical variable (age at diagnosis and sex) only, radiomics only, and radiomics plus clinical variable. Concordance metric was used to assess the Cox model. RESULTS: Nine radiomic features were selected from T1gad (2 texture wavelet) and T2 (5 first-order features (1 original, 4 wavelet), 2 texture features (1 wavelet, 1 log-sigma). This model demonstrated significantly higher performance than a clinical model alone (C: 0.68 vs 0.59, p<0.001). Adding clinical features to radiomic features slightly improved prediction, but was not significant (C=0.70, p=0.06). CONCLUSION: Our pilot study shows a potential role for MRI-based radiomics and machine learning for DMG risk stratification and as image-based biomarkers for clinical therapy trials.
format Online
Article
Text
id pubmed-7715677
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77156772020-12-09 IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA Tam, Lydia Han, Michelle Wright, Jason Toescu, Sebastien Campion, Andrew Shpanskaya, Katie Mankad, Kshitij Ho, Chang Lober, Robert Cheshier, Samuel Hargrave, Darren Jacques, Tom Aquilina, Kristian Monje, Michelle Grant, Gerald Mattonen, Sarah Vitanza, Nick Yeom, Kristen Neuro Oncol Imaging BACKGROUND: Diffuse midline gliomas (DMG) are lethal pediatric brain tumors with dismal prognoses. Presently, MRI is the mainstay of disease diagnosis and surveillance. We aimed to identify prognostic image-based radiomics markers of DMG and compare its performance to clinical variables at presentation. METHODS: 104 treatment-naïve DMG MRIs from five centers were used (median age=6.5yrs; 18 males, median OS=11mos). We isolated tumor volumes of T1-post-contrast (T1gad) and T2-weighted (T2) MRI for PyRadiomics high-dimensional feature extraction. 900 features were extracted on each image, including first order statistics, 2D/3D Shape, Gray Level Co-occurrence Matrix, Gray Level Run Length Matrix, Gray Level Size Zone Matrix, Neighboring Gray tone Difference Matrix, and Gray Level Dependence Matrix, as defined by Imaging Biomarker Standardization Initiative. Overall survival (OS) served as outcome. 10-fold cross-validation of LASSO Cox regression was used to predict OS. We analyzed model performance using clinical variable (age at diagnosis and sex) only, radiomics only, and radiomics plus clinical variable. Concordance metric was used to assess the Cox model. RESULTS: Nine radiomic features were selected from T1gad (2 texture wavelet) and T2 (5 first-order features (1 original, 4 wavelet), 2 texture features (1 wavelet, 1 log-sigma). This model demonstrated significantly higher performance than a clinical model alone (C: 0.68 vs 0.59, p<0.001). Adding clinical features to radiomic features slightly improved prediction, but was not significant (C=0.70, p=0.06). CONCLUSION: Our pilot study shows a potential role for MRI-based radiomics and machine learning for DMG risk stratification and as image-based biomarkers for clinical therapy trials. Oxford University Press 2020-12-04 /pmc/articles/PMC7715677/ http://dx.doi.org/10.1093/neuonc/noaa222.346 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Imaging
Tam, Lydia
Han, Michelle
Wright, Jason
Toescu, Sebastien
Campion, Andrew
Shpanskaya, Katie
Mankad, Kshitij
Ho, Chang
Lober, Robert
Cheshier, Samuel
Hargrave, Darren
Jacques, Tom
Aquilina, Kristian
Monje, Michelle
Grant, Gerald
Mattonen, Sarah
Vitanza, Nick
Yeom, Kristen
IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA
title IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA
title_full IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA
title_fullStr IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA
title_full_unstemmed IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA
title_short IMG-10. MRI-BASED RADIOMIC PROGNOSTIC MARKERS OF DIFFUSE MIDLINE GLIOMA
title_sort img-10. mri-based radiomic prognostic markers of diffuse midline glioma
topic Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715677/
http://dx.doi.org/10.1093/neuonc/noaa222.346
work_keys_str_mv AT tamlydia img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT hanmichelle img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT wrightjason img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT toescusebastien img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT campionandrew img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT shpanskayakatie img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT mankadkshitij img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT hochang img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT loberrobert img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT cheshiersamuel img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT hargravedarren img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT jacquestom img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT aquilinakristian img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT monjemichelle img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT grantgerald img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT mattonensarah img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT vitanzanick img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma
AT yeomkristen img10mribasedradiomicprognosticmarkersofdiffusemidlineglioma